Why Insurance Churn Becomes a Mortality Risk in Opioid Use Disorder

Why Coverage Loss Is a Clinical Event

Insurance disenrollment is often described in administrative language: eligibility, plan change, lapse, transition, renewal failure. In opioid use disorder, that language can hide the clinical reality. For a patient who has just started medication treatment, losing coverage may mean losing the prescriber, the pharmacy pathway, the follow-up visit, the care coordinator, the behavioral health referral, or access to naloxone.

That makes health-plan disenrollment more than a paperwork problem. After initiation of medications for opioid use disorder (MOUD), continuity becomes part of treatment. Buprenorphine and naltrexone are not one-time interventions. They depend on persistence, monitoring, dose adjustment, patient trust, and a care system capable of responding when risk changes.

The JAMA Psychiatry cohort study on health-plan disenrollment and mortality after MOUD initiation should therefore be read as a public mental health article, not simply as an addiction pharmacotherapy paper.¹ The stronger question is what happens when patients begin evidence-based treatment and then lose the coverage structure that helps keep that treatment in place.

What the Study Actually Asked

The study examined privately and publicly insured patients aged 16 years or older who initiated buprenorphine or naltrexone for opioid use disorder between January 1, 2012, and December 31, 2021. The cohort came from three integrated health-insurance and care-delivery systems in two US states. Patients were followed for up to two years, through December 31, 2022.

1. Identify treatment startsPatients beginning buprenorphine or naltrexone for OUD
2. Track coverageDetermine whether health-plan disenrollment occurred
3. Link mortality dataUse the National Death Index to identify deaths
4. Compare riskAdjust analyses for measured demographic and clinical factors

OUD: opioid use disorder. MOUD: medications for opioid use disorder.

The outcomes were all-cause mortality and drug-related and alcohol-related overdose mortality within two years of treatment initiation. The analysis adjusted for sociodemographic and clinical characteristics.

This design matters because observation started after treatment initiation. The policy question is not only whether people can access MOUD in the first place, although that remains essential. It is whether patients can stay connected to coverage and care once treatment has begun. In addiction care, initiation is often treated as the milestone; this study shifts attention to what happens next.

The mean age was 38.7 years, and 61.5% of patients were male. During follow-up, 6,948 people experienced health-plan disenrollment. More than one-third of patients starting MOUD therefore had a disruption in plan enrollment within the observation period.

What the Results Showed

During follow-up, 586 patients, or 2.9%, died. Across the whole cohort, the crude all-cause mortality rate was 15.3 per 1,000 person-years and the overdose mortality rate was 6.2 per 1,000 person-years. Both rates were higher among patients who experienced disenrollment than among those who remained enrolled.

After adjustment for measured differences between patients, health-plan disenrollment remained associated with higher mortality.

Another comparison sharpened the clinical picture. Relative to patients who remained enrolled and continued receiving MOUD, both being disenrolled and being enrolled without receiving MOUD were associated with markedly higher overall mortality.

The magnitude and consistency of the pattern are nevertheless difficult to dismiss. Coverage disruption after MOUD initiation marks a period in which patients may need additional protection.

Why Disenrollment Can Become Dangerous After MOUD Initiation

MOUD is often discussed through medication names: buprenorphine, methadone, and naltrexone. In practice, treatment is a continuity-dependent pathway. A patient needs refills, follow-up, monitoring, insurance authorization, pharmacy access, dose adjustment, and a clinician who can respond to withdrawal, cravings, relapse risk, side effects, depression, pain, or polysubstance use.

1. Coverage lossPlan ends or eligibility changes
2. Care disruptionPrescriber, pharmacy, or appointment becomes inaccessible
3. Medication gapRefills or monitored treatment are interrupted
4. Return to useCraving, withdrawal, or destabilization increases risk
5. Overdose exposureLower tolerance and a potent illicit supply can converge

This is a plausible clinical pathway, not proof that every disenrollment follows the same sequence.

Disenrollment can break treatment at several points. A patient may lose access to a prescriber or covered pharmacy. A new plan may have different networks, formularies, prior-authorization rules, or visit requirements. A lapse may create out-of-pocket costs that are impossible to manage. Even short gaps can force someone to restart intake procedures or navigate a new system while already clinically vulnerable.

In opioid use disorder, gaps in care are not neutral. Interruption of medication can increase cravings and return-to-use risk. If tolerance declines and the patient returns to an illicit opioid supply containing fentanyl or another potent synthetic opioid, overdose risk can rise sharply.

Risk may become still more complex when opioid exposure overlaps with alcohol, benzodiazepines, or gabapentinoids. The site’s review of gabapentinoid misuse, polysubstance use, and overdose mortality explains why combinations of central nervous system depressants require particular attention.

Insurance churn may also reflect broader instability. People can lose coverage because of job loss, income changes, incarceration, housing disruption, relocation, administrative errors, or failure to complete renewal paperwork. These are not random inconveniences. They often cluster with the same social and clinical risks that make overdose more likely.

That is why the study should not be read as a story about patient nonadherence. Someone may appear “lost to follow-up” in a clinical record, while the underlying mechanism is structural: coverage loss, network disruption, unaffordable care, or administrative burden. Systems often demand stability from people at the exact moment when their lives are least stable.

What This Means for Policy and Health Systems

If disenrollment after MOUD initiation is associated with mortality, continuity of coverage should be treated as part of overdose prevention. This requires a broader policy lens than simply encouraging clinicians to prescribe more buprenorphine or naltrexone. Initiation remains essential, but it is not enough.

• Bridge medication access during temporary insurance gaps or plan transitions.
• Trigger proactive outreach when coverage, appointments, or medication fills lapse.
• Support rapid re-enrollment instead of leaving patients to restart alone.
• Preserve continuity across plans through network, formulary, and authorization safeguards.
• Provide naloxone before transitions and renew overdose-prevention education.
• Use warm handoffs when patients must change clinicians, pharmacies, or care networks.

Integrated systems may be better positioned than fragmented systems to detect missed visits, coverage lapses, and medication gaps. Yet disenrollment was common even in the integrated systems studied. In more fragmented settings, the problem may be harder to see and manage.

Well-designed digital and telepsychiatric care pathways may help preserve contact during transitions, but technology cannot replace insurance coverage, medication access, or a clinician able to assume responsibility for continuing care.

The findings also challenge how success is measured. A health system may celebrate MOUD initiation rates while ignoring later disruption. A payer may approve medication but allow coverage churn to interrupt care. A policy may expand access on paper while leaving patients exposed during renewal, plan switching, or eligibility changes.

For opioid use disorder, the treatment chain has multiple weak links. Prescription access is one; coverage continuity is another. The study suggests that losing the second can undermine the first.

What the Study Does—and Does Not—Prove

Residual confounding is possible. Patients who disenroll may differ from those who remain enrolled in ways that claims and clinical data cannot fully capture. The cohort came from three integrated systems in two US states, so the findings should be generalized carefully.

Nevertheless, the association is clinically and politically important. Among patients who started MOUD, disenrollment was common and linked to higher all-cause and overdose mortality. That is enough to treat insurance churn as a risk signal rather than a routine administrative event.

The practical conclusion is direct: overdose prevention is not only about which medication is prescribed. It is also about whether patients can remain connected to coverage and care after treatment begins. In opioid use disorder, a lapse in insurance can become a break in the treatment chain at the point when continuity may matter most.

Questions Readers Often Ask